Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKAR | P32238 | 4/20 | 0.60 |
| ▸ | CCKBR | P32239 | 4/20 | 0.60 |
| ▸ | CTSS | P25774 | 4/20 | 0.57 |
| ▸ | CTSK | P43235 | 4/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.57 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31628521 | 0.79 | SCN9A (0.65) | CCKARCCKBRCTSSCTSKCTSL | |
| SCHEMBL20030540 | 0.78 | SCN9A (0.56) | CCKARCCKBRCTSSCTSKCTSL | |
| SCHEMBL30279703 | 0.77 | CTSS (0.73) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL6163314 | 0.77 | CTSS (0.73) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL6163823 | 0.77 | CTSS (0.73) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL6163323 | 0.77 | CTSS (0.73) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL8951298 | 0.77 | CTSS (0.73) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL22618478 | 0.77 | CTSS (0.59) | CCKARCCKBRCTSSCTSKCTSL | |
| SCHEMBL22618535 | 0.77 | CTSS (0.59) | CCKARCCKBRCTSSCTSKCTSL | |
| SCHEMBL21219305 | 0.76 | ACE (0.72) | CTSSCTSKCTSLCTSBAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263486-A1 | Inhibitors of Cancer Cell, T-Cell and Keratinocyte Proliferation | 4SC AG (DE) | 2011-10-27 | — | — | US | disclosed |
| EP-2284179-A2 | Inhibitors of cancer cell, T-cell and keratinocyte proliferation | 4SC AG (DE) | 2011-02-16 | — | — | EP | disclosed |
| EP-2284178-A2 | Inhibitors of cancer cell, T-cell and keratinocyte proliferation | 4SC AG (DE) | 2011-02-16 | — | — | EP | disclosed |
| US-20090176716-A1 | INHIBITORS OF CANCER CELL, T-CELL AND KERATINOCYTE PROLIFERATION | LEBAN JOHANN | 2009-07-09 | — | — | US | disclosed |
| US-7531517-B2 | Inhibitors of cancer cell, T-cell and keratinocyte proliferation | 4SC AG (DE) | 2009-05-12 | — | — | US | disclosed |
| US-20070037753-A1 | Inhibitors of cancer cell, T-cell and keratinocyte proliferation | 4SC AG (DE) | 2007-02-15 | — | — | US | disclosed |
| EP-1752467-A1 | Inhibitors of cancer cell, t-cell and keratinocyte proliferation | 4SC AG (DE) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176716-A1 | INHIBITORS OF CANCER CELL, T-CELL AND KERATINOCYTE PROLIFERATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EGFR, MKI67 | CCKAR 166/4885CCKBR 427/4885CTSS 1617/4885 |
| US-20070037753-A1 | Inhibitors of cancer cell, T-cell and keratinocyte proliferation | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EGFR, MKI67 | CCKAR 150/4885CCKBR 346/4885CTSS 1523/4885 |
| US-20110263486-A1 | Inhibitors of Cancer Cell, T-Cell and Keratinocyte Proliferation | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EGFR, MKI67 | CCKAR 172/4885CCKBR 411/4885CTSS 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.